CureVac NV (Germany) Performance
| 5CV Stock | EUR 2.78 0.03 1.07% |
CureVac NV has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0576, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CureVac NV are expected to decrease at a much lower rate. During the bear market, CureVac NV is likely to outperform the market. CureVac NV right now shows a risk of 4.74%. Please confirm CureVac NV jensen alpha, sortino ratio, and the relationship between the standard deviation and total risk alpha , to decide if CureVac NV will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CureVac NV are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, CureVac NV may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 1.3 B | |
| Total Cashflows From Investing Activities | -127.9 M |
CureVac |
CureVac NV Relative Risk vs. Return Landscape
If you would invest 272.00 in CureVac NV on December 18, 2024 and sell it today you would earn a total of 6.00 from holding CureVac NV or generate 2.21% return on investment over 90 days. CureVac NV is currently producing 0.1431% returns and takes up 4.7442% volatility of returns over 90 trading days. Put another way, 42% of traded stocks are less volatile than CureVac, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CureVac NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CureVac NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CureVac NV, and traders can use it to determine the average amount a CureVac NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | 5CV | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.74 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average CureVac NV is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CureVac NV by adding it to a well-diversified portfolio.
CureVac NV Fundamentals Growth
CureVac Stock prices reflect investors' perceptions of the future prospects and financial health of CureVac NV, and CureVac NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CureVac Stock performance.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.34 | |||
| Profit Margin | (1.26) % | |||
| Operating Margin | (7.27) % | |||
| Current Valuation | 792.23 M | |||
| Shares Outstanding | 221.98 M | |||
| Price To Book | 2.07 X | |||
| Price To Sales | 13.59 X | |||
| Revenue | 102.99 M | |||
| EBITDA | (386.49 M) | |||
| Cash And Equivalents | 1.33 B | |||
| Cash Per Share | 7.34 X | |||
| Total Debt | 55.28 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 3.29 X | |||
| Cash Flow From Operations | (733.13 M) | |||
| Earnings Per Share | (0.63) X | |||
| Total Asset | 1.16 B | |||
About CureVac NV Performance
By analyzing CureVac NV's fundamental ratios, stakeholders can gain valuable insights into CureVac NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CureVac NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CureVac NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. CUREVAC N operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 455 people.Things to note about CureVac NV performance evaluation
Checking the ongoing alerts about CureVac NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CureVac NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CureVac NV had very high historical volatility over the last 90 days | |
| The company reported the revenue of 102.99 M. Net Loss for the year was (411.72 M) with loss before overhead, payroll, taxes, and interest of (135.09 M). | |
| CureVac NV has accumulated about 1.33 B in cash with (733.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 46.0% of the company shares are owned by insiders or employees |
- Analyzing CureVac NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CureVac NV's stock is overvalued or undervalued compared to its peers.
- Examining CureVac NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CureVac NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CureVac NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CureVac NV's stock. These opinions can provide insight into CureVac NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |